United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,105 shares of the biotechnology company’s stock after selling 61 shares during the period. Flagship Harbor Advisors LLC’s holdings in United Therapeutics were worth $341,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC boosted its holdings in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 30 shares during the period. Parallel Advisors LLC boosted its stake in shares of United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC boosted its stake in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC grew its position in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer now owns 8,118 shares of the company’s stock, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at approximately $11,261,606.58. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,681 shares of company stock valued at $24,177,219. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 1.4%

NASDAQ:UTHR opened at $285.97 on Thursday. The company has a market capitalization of $12.90 billion, a PE ratio of 11.41, a P/E/G ratio of 6.35 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The stock’s 50 day moving average price is $301.15 and its 200 day moving average price is $326.23.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.17 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on UTHR shares. Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research note on Wednesday, June 11th. Wells Fargo & Company restated an “equal weight” rating and issued a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Wall Street Zen cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. Morgan Stanley increased their target price on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a report on Thursday, May 1st. Finally, JPMorgan Chase & Co. cut their price target on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $393.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.